TY - JOUR
T1 - A new genetic isolate of gray platelet syndrome (GPS)
T2 - Clinical, cellular, and hematologic characteristics
AU - Falik-Zaccai, Tzipora C.
AU - Anikster, Yair
AU - Rivera, Candido E.
AU - Horne, McDonald K.
AU - Schliamser, Liliana
AU - Phornphutkul, Chanika
AU - Attias, Dina
AU - Hyman, Tehila
AU - White, James G.
AU - Gahl, William A.
N1 - Funding Information:
*Division of Medical Genetics, Hospital of Western Galillee-Naharia, Rappaport Faculty of Medicine, Technion, Haifa, Israel; †Section on Human Biochemical Genetics, Heritable Disorders Branch, National Institute of Child Health and Human Development, National Institutes of Health (NIH), Bethesda, Maryland 20892; ‡Department of Laboratory Medicine, Division of Hematology, W. G. Magnuson Clinical Center, NIH, Bethesda, Maryland 20892; §Hematology Institute, Bnai Zion Medical Center, Haifa Israel; ¶Laboratory of Cellular Carcinogenesis and Tumor Promotion, National Cancer Institute, NIH, Bethesda, Maryland 20892; and ‖Department of Laboratory Medicine, University of Minnesota, Minneapolis, Minnesota 55455
PY - 2001
Y1 - 2001
N2 - Gray platelet syndrome (GPS) is a disorder characterized by thrombocytopenia and large platelets that lack α granules and their contents. We describe two siblings with GPS who are members of a Moslem Bedouin genetic isolate. The children, an 8-year-old girl and a 5-year-old boy, had characteristic pale blue platelets lacking α granules on electron microscopy. Platelet aggregation studies were normal. The girl underwent a bone marrow aspiration and biopsy which showed mild myelofibrosis and extensive emperipolesis, i.e., the passage of other hematopoietic cells through megakaryocytes. Both children lacked high-molecular-weight multimers of von Willebrand factor (vWF) and had reduced activity and antigens of vWf. Platelet activation was approximately normal when ADP was employed as agonist, but significantly impaired using the thrombin receptor-activating peptide (TRAP). These findings are explained in light of the mechanism of action of each agonist. In addition, we propose that the emperipolesis was caused by increased P-selectin in megakaryocytes, and resulted in release of fibroblastic growth factors, explaining the myelofibrosis. The detailed description of these cases provides a basis for future differentiation of the various types of GPS, and for our current attempts to isolate the gene causing GPS in this genetic isolate.
AB - Gray platelet syndrome (GPS) is a disorder characterized by thrombocytopenia and large platelets that lack α granules and their contents. We describe two siblings with GPS who are members of a Moslem Bedouin genetic isolate. The children, an 8-year-old girl and a 5-year-old boy, had characteristic pale blue platelets lacking α granules on electron microscopy. Platelet aggregation studies were normal. The girl underwent a bone marrow aspiration and biopsy which showed mild myelofibrosis and extensive emperipolesis, i.e., the passage of other hematopoietic cells through megakaryocytes. Both children lacked high-molecular-weight multimers of von Willebrand factor (vWF) and had reduced activity and antigens of vWf. Platelet activation was approximately normal when ADP was employed as agonist, but significantly impaired using the thrombin receptor-activating peptide (TRAP). These findings are explained in light of the mechanism of action of each agonist. In addition, we propose that the emperipolesis was caused by increased P-selectin in megakaryocytes, and resulted in release of fibroblastic growth factors, explaining the myelofibrosis. The detailed description of these cases provides a basis for future differentiation of the various types of GPS, and for our current attempts to isolate the gene causing GPS in this genetic isolate.
KW - Fibrinogen receptor
KW - Genetic isolate
KW - Gray platelet syndrome
KW - P-selectin
UR - http://www.scopus.com/inward/record.url?scp=0035196989&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035196989&partnerID=8YFLogxK
U2 - 10.1006/mgme.2001.3247
DO - 10.1006/mgme.2001.3247
M3 - Article
C2 - 11708859
AN - SCOPUS:0035196989
SN - 1096-7192
VL - 74
SP - 303
EP - 313
JO - Biochemical Medicine and Metabolic Biology
JF - Biochemical Medicine and Metabolic Biology
IS - 3
ER -